Articles tagged with Cancer Medication
Researchers reanalyzed data from the Prostate Cancer Prevention Trial, finding that prostate shrinkage may be responsible for the excess prevalence of high-grade cancer in the drug-treated group. Adjusting for changes in gland size due to finasteride use eliminated all excess high-grade tumors.
Researchers at Rice University have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres, creating a uniform delivery system that targets cancer cells more effectively. The new approach aims to reduce side effects and improve the effectiveness of chemotherapy.
A new study suggests that finasteride, a generic drug for enlarged prostates, improves early detection of fast-growing prostate cancers. Finasteride reduces prostate size and cancer risk by 25 percent, making it easier for physicians to detect high-grade tumors early.
Two studies found that finasteride reduces prostate cancer incidence, but increases detection of high-grade cancers. Analysis suggests increased detection rather than development of high-grade cancers. The findings have favorable implications for the clinical impact of finasteride.
The Oregon Health & Science University School of Medicine is part of a national team researching ways to preserve or restore fertility in women with cancer. Researchers are studying methods to freeze and store ovary tissue and grow follicles in culture, aiming to help young cancer patients have children.
A genetic variant in nearly half of Americans with European ancestry is linked to greater effectiveness of bupropion in quitting smoking. People with the variant were less likely to resume smoking six months after treatment.
Studies show that up to 50% of patients with advanced cancer suffer from major psychiatric disorders, including adjustment disorders, anxiety disorders, and depressive disorders. Effective communication, emotional support, and screening can help manage these conditions, reducing psychological distress and improving quality of life.
Postmenopausal women consuming two or more alcoholic beverages daily may double their risk of endometrial cancer, according to a USC study. The study found that lean women are more sensitive to alcohol's effects on hormone levels, increasing their cancer risk.
A new study from the University of Michigan Comprehensive Cancer Center found that nearly half of women with breast cancer experience musculoskeletal issues while taking aromatase inhibitors. Up to 15% of patients stop treatment due to these side effects, highlighting a need for interventions to manage symptoms.
Researchers at the University of Texas M. D. Anderson Cancer Center found that congestive heart failure is rare among leukemia patients taking imatinib. Only 22 out of 1,276 patients developed symptoms that could be caused by heart failure, and most had underlying medical conditions that also contributed to their condition.
A study found that hepatitis C and B virus infections are spreading less quickly among injection drug users in San Francisco. This decrease is attributed to reduced needle-sharing, a common method of transmission.
Researchers have identified a promising drug combination that may help treat metastatic uveal melanoma, a rare and aggressive form of the disease. The combination of decitabine and interferon gamma has shown to cause cancer cell death in human cell lines derived from patients with uveal melanoma.
Researchers found that an important melanoma treatment has little effect on cancer cells themselves, but instead boosts immune system cells. The study highlights the need to develop ways to make melanoma cells more vulnerable to the drug or overcome the block within cells that prevents them from responding.
A Johns Hopkins study shows an experimental compound called cyclopamine successfully kills cancer stem cells that fuel tumor growth and help cancers evade drug and radiation therapy. The study provides evidence for a potential new therapy for glioblastoma, a deadly brain cancer.
Liang’s research aims to develop ‘smart’ peptide drugs that can selectively kill cancer cells without damaging normal tissues. These peptide drugs have shown high activity against both drug-sensitive and drug-resistant cancers in studies on cultured tumor cells and animal models.
A leading epidemiologist attacks a Swedish research report on cancer drug access, citing flawed methods, incorrect conclusions, and potential industry influence. The Karolinska report aimed to link national cancer survival rates with access to cancer drugs, but its methodology has been disputed.
A study of 13,001 RA patients reveals that biologic treatment increases the risk of skin cancers, including melanoma, but not other types of cancer. The research suggests that current biologic therapy may be safe for RA patients, providing reassurance for those considering treatment.
Researchers at the University of North Carolina analyzed data from nine studies and found that patients with a specific gene variation had a greater risk of side effects when taking medium or high doses of irinotecan. The study suggests that the FDA should modify its guidelines to reflect this finding.
Researchers have discovered a specific form of estrogen that can protect the brain from degeneration without increasing cancer risk. This 'designer estrogen' offers potential for treating multiple sclerosis and combating other age-related brain diseases.
Researchers at Ohio State University have identified a new potential treatment for leukemia, FTY720, which prevents disease in mouse models of various leukemias. The drug activates tumor suppressor PP2A, reactivating it in cancer cells.
The American Chemical Society (ACS) is presenting several groundbreaking research developments related to nanotechnology and biotechnology. Researchers from Harvard University, the California Institute of Technology, and Northwestern University will discuss new technologies that aim to improve human health and productivity in the futur...
Researchers at Stanford Medicine have identified a pattern of gene expression shared by patients who successfully stopped taking anti-rejection drugs. This discovery may allow some transplant patients to reduce or eliminate their lifelong dependence on immunosuppressive drugs, improving their quality of life.
Researchers identified an unusually high rate of severe allergic reactions to cetuximab among patients living in the middle South, with a 22% rate compared to 2% nationwide. The strongest predictor of a reaction was a history of other hypersensitivities.
Researchers at McMaster University have discovered a new molecular zip code and potential drug target for Huntington's disease. They found that mutant huntingtin protein can be prevented from entering the nucleus by kinase inhibitors, which may lead to effective treatment options.
Researchers investigating chronic myeloid leukemia treatment options suggest combining drugs to combat resistance, while others explore targeting prostaglandin E2 receptor EP1 for hypertension therapy. Additionally, a study reveals that Sphingosine 1-phosphate receptor 2 deficiency prevents abnormal blood vessel formation in the retina.
Researchers suggest treating CML patients with a combination of imatinib and dasatinib to prevent BCR-ABL mutants that are resistant to both drugs. A study found that combining the two drugs can increase time before relapse or decrease chance of cancer return.
A study by University of Toronto researchers found significant differences in breast cancer prevention practices among Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Women in Quebec were the least likely to use preventive measures, with only 38% opting for surgery or medication.
Researchers found that metformin slows tumor growth in mice with colon cancer lacking the regulatory gene p53. The study's findings may lead to new therapies for aggressive and resistant human cancers.
A new MIT model can predict how cells will respond to targeted drug therapies, enabling better treatment choices for individual patients. The model is based on similarities in cell signaling pathways and could help test the effectiveness of drugs for various diseases.
A combination of two drugs, interferon alpha and sorafenib, is more effective than either drug alone in treating renal cell carcinoma, the most common form of kidney cancer. The treatment doubles the survival time of patients with stage IV disease.
A study led by Duke University researchers found that a white blood cell booster can significantly reduce the risk of chemotherapy-related complications characterized by fever and low white blood cell levels. The study, published in the Journal of Clinical Oncology, involved over 3,000 patients and showed that patients taking the drug ...
Testicular cancer patients with metastatic disease can be cured with high-dose chemotherapy and a stem cell transplant, as shown in an Indiana University School of Medicine report. The treatment, which involves carboplatin chemotherapy at five times the standard dosage, has a success rate of over 90%.
A new study published in CANCER found that newer drug therapies, particularly aromatase inhibitors, have improved the survival of women with metastatic breast cancer. Survival rates increased by approximately 30% as these drugs became more widely used between 1991 and 2001.
Researchers have developed an algorithm that can match any tumor cells with the most effective anti-cancer treatments, predicting clinical responses and identifying new compounds. This 'coexpression extrapolation (COXEN) system' has been successfully tested on bladder cancer cell lines and shows promise for other types of cancer.
A large study of over 17,000 men found that finasteride caused a small decrease in sexual function, but this effect diminished over time. The researchers concluded that finasteride is unlikely to cause significant sexual dysfunction for most men taking the drug.
The Case Comprehensive Cancer Center has received a $25.5 million award from the National Cancer Institute, representing a 10% increase in funding. The center, one of only 40 nationwide to receive an increase, will allocate $5.1 million annually for five years.
Researchers propose a 'value meal' approach to decrease medication costs while increasing benefits from expensive cancer drugs. By taking certain medications with meals or grapefruit juice, patients may use up to 80% of the prescribed dose and reduce side effects.
A new study demonstrates that ABT-737 can enhance the combined toxicity of common drugs against leukemia cells, leading to improved treatment outcomes. The results provide hope for children with Acute Lymphoblastic Leukemia (ALL), a common form of childhood cancer.
Researchers at the University of Pennsylvania School of Medicine identified a combination therapy that selectively eliminates cancer cells while leaving healthy cells intact. The therapy combines TRAIL and sorafenib, reducing tumor size in mice with few side effects, demonstrating its potential effectiveness on human colon cancers.
Researchers have discovered that p27 can act as both a CDK-dependent tumor suppressor and a CDK-independent oncogene. This finding has significant implications for understanding cancer growth and developing drugs to target p27 dysfunction.
The FDA review found no strong association between eating tomatoes and decreased cancer risk, but some limited evidence for associations with prostate, ovarian, gastric, and pancreatic cancers. The agency allowed qualified health claims for these four cancers, citing very limited and preliminary scientific research.
Postmenopausal Asian women who consume a meat-sweet Western diet are at higher risk of developing breast cancer compared to those on a vegetable-soy diet, according to the study. The researchers found that high intake of the meat-sweet pattern increased estrogen-receptor-positive breast cancer among overweight postmenopausal women.
A study found a significant association between the Western-style 'meat-sweet' diet and an increased risk of breast cancer among postmenopausal Chinese women, particularly those with estrogen receptor-positive tumors. The research suggests that low consumption of this dietary pattern may protect against breast cancer.
Researchers developed a new drug delivery method using ultrasound to target cancer tumors, releasing chemotherapy drugs from nanobubbles. They found this approach was more effective at blocking tumor growth than other nanoparticle delivery methods. Vitamin D levels were also associated with reduced colon cancer risk in a separate study.
Scientists at Wake Forest University School of Medicine have discovered that an obesity drug, orlistat, can be repurposed to target and kill cancer cells. The breakthrough, published in Nature Structural and Molecular Biology, provides a promising new avenue for the development of more potent cancer treatments.
A novel mutation of the AKT1 gene has been found in breast, colorectal, and ovarian cancers, which may contribute to tumor cell proliferation. The mutation is believed to play a role in making cells resistant to certain therapies.
Cancer researcher Peter Duesberg's chromosomal theory of cancer suggests that each cancer is unique and resistant to drugs due to aneuploidy, a chromosomal disruption that can be seen easily through a microscope. This theory supports the development of drug resistance in cancer cells.
Researchers have developed a new drug delivery method using nanoparticles that carries the chemotherapy drug doxorubicin deeper into solid tumors, improving its effectiveness. This treatment approach resulted in increased tumor growth prevention and longer survival times for mice compared to traditional methods.
A large-scale comparative study has found that treatment with intravenous bisphosphonates increases the risk of jaw or facial bone disease or infection. After six years, about 5.5% of bisphosphonate users had undergone facial or jaw bone surgery or been diagnosed with inflammation of the jaw bone, compared to 0.3% of non-users.
Bisphosphonates may cause osteonecrosis of the jaws in patients taking these medications. Women should inform their dentists if they take bisphosphonates to reduce risk. Meanwhile, Burning Mouth Syndrome can be caused by xerostomia, and treatment depends on the patient's condition.
Delft scientists observe topotecan's effect on DNA molecule loops, revealing mechanism of TopoIB protein in cell division. They use magnetic spheres and magnets to manipulate a single DNA molecule, allowing them to study the enzyme's action live.
Researchers at Goethe University Frankfurt have identified a novel Ub conjugation reaction that allows for more efficient manipulation of key proteins in the treatment of cancer and other diseases. This discovery provides a basis for novel therapeutic approaches that are more specific than existing drugs like Bortezomib.
Researchers at Weill Cornell Medical College have discovered two potential points of vulnerability in the XIAP protein, a key player in cancer cell survival. Targeting these activities could lead to tumor cell death and reduced tumors.
A retrospective study found that trabectedin response rates were significantly higher than previous studies, with an overall response rate of 51% and a progression-free survival rate of 88%. This suggests that myxoid sarcoma may be a uniquely sensitive subgroup to trabectedin treatment.
Researchers at University of Alberta developed a microfluidic chip for faster and cheaper FISH cancer diagnosis, enabling widespread use and personalized treatment strategies. The technology could significantly increase cancer detection speed and reduce costs from hundreds to tens of dollars.
Kurt C. Stange has been named an American Cancer Society Clinical Research Professor, a prestigious award recognizing his innovative research on cancer prevention and treatment. The five-year grant will support work to identify emerging models of personalized, integrated care.
Researchers have successfully sequenced the genome of Salinispora tropica, a bacterium discovered in Bahamian mud with potential to produce compounds showing promise in treating diseases such as cancer. The decoded genome reveals an impressive 10% of genes dedicated to producing molecules for antibiotics and anticancer agents.
A new study by VCU researchers identifies the mechanism of action used by anti-cancer drug sorafenib, which inhibits protein translation and reduces expression of pro-survival factors. This finding may lead to the development of novel regimens combining sorafenib with other molecularly targeted agents.
U-M researchers found that a gene called Brahma is silent in some cancer cells but can be reactivated using inhibitor drugs. The study shows promise for developing new targeted therapies to slow or stop cancer progression.
Researchers discovered that lapatinib activates a protective pathway in heart cells, while trastuzumab does not. This difference may lead to the development of new drugs with fewer cardiovascular side effects.